Skip to main content
. 2014 Mar 4;7(5):1083–1088. doi: 10.3892/etm.2014.1599

Figure 2.

Figure 2

Survival time curves of the patients in each group. Median survival times were 27, 33, 32 and 36 months in the control, neoadjuvant chemotherapy, hyperthermic intraperitoneal perfusion chemotherapy and joint groups, respectively; the differences between the four groups were statistically significant (χ2, 10.37; P=0.001).